Jacobs Levy Equity Management Inc. Makes New Investment in Orthofix Medical Inc. $OFIX

Key Points

• Jacobs Levy Equity Management Inc. acquired a new stake in Orthofix Medical, purchasing 64,230 shares valued at approximately $1.05 million, representing about 0.16% of the company's stock.
• Insider Aviva Mcpherron sold 3,728 shares of Orthofix Medical at an average price of $10.51, decreasing their position by 7.45%.
• Orthofix Medical reported earnings of (\$0.36) per share, missing the consensus estimate, but generated revenue of $203.12 million in the recent quarter.

Jacobs Levy Equity Management Inc. purchased a new stake in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 64,230 shares of the medical device company's stock, valued at approximately $1,048,000. Jacobs Levy Equity Management Inc. owned approximately 0.16% of Orthofix Medical as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Engine Capital Management LP lifted its holdings in shares of Orthofix Medical by 8.4% in the first quarter. Engine Capital Management LP now owns 3,741,390 shares of the medical device company's stock valued at $61,022,000 after purchasing an additional 290,646 shares in the last quarter. Juniper Investment Company LLC increased its position in Orthofix Medical by 10.3% during the first quarter. Juniper Investment Company LLC now owns 2,137,374 shares of the medical device company's stock worth $34,861,000 after buying an additional 200,125 shares during the last quarter. Nuveen LLC acquired a new position in Orthofix Medical during the first quarter worth $1,445,000. Soleus Capital Management L.P. increased its position in Orthofix Medical by 13.1% during the fourth quarter. Soleus Capital Management L.P. now owns 686,374 shares of the medical device company's stock worth $11,984,000 after buying an additional 79,441 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in shares of Orthofix Medical by 421.1% in the first quarter. Assenagon Asset Management S.A. now owns 72,226 shares of the medical device company's stock valued at $1,178,000 after purchasing an additional 58,366 shares during the last quarter. Institutional investors and hedge funds own 89.76% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on OFIX shares. JMP Securities reaffirmed a "market perform" rating on shares of Orthofix Medical in a research report on Friday, June 6th. Barrington Research upgraded shares of Orthofix Medical to a "strong-buy" rating and set a $16.00 target price for the company in a research note on Monday, June 23rd. Finally, Wall Street Zen upgraded shares of Orthofix Medical from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $21.50.

Orthofix Medical Stock Performance

Orthofix Medical stock traded up $0.10 during trading hours on Wednesday, hitting $14.94. The company had a trading volume of 256,734 shares, compared to its average volume of 414,504. The firm has a market cap of $589.98 million, a PE ratio of -4.71 and a beta of 0.86. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.67 and a quick ratio of 1.50. Orthofix Medical Inc. has a one year low of $10.24 and a one year high of $20.73. The firm has a 50-day moving average of $13.13 and a 200 day moving average of $13.21.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.40). Orthofix Medical had a negative return on equity of 25.43% and a negative net margin of 15.29%.The business had revenue of $203.12 million for the quarter, compared to analyst estimates of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Orthofix Medical Inc. will post -2.81 earnings per share for the current year.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.